Can A Drug That Delays The Onset Of Type 1 Diabetes Be A Success?

Given the autoimmune nature of type 1 diabetes, researchers have sought to control, or perhaps even halt, its progress by administering drugs that theoretically could block an overactive immune system from attacking the pancreas. Back in 2010, Lilly actually studied one of its drugs, teplizumab, an anti-CD3 antibody to see if it could do just that.